1 | prolate or nalocet tablets | | | | | | | 7 | 1.15% |
2 | addiction abuse and misuse | | | | | | | 4 | 0.66% |
3 | benzodiazepines or other cns | | | | | | | 3 | 0.49% |
4 | of prolate or nalocet | | | | | | | 3 | 0.49% |
5 | partnering company partnering contact | | | | | | | 2 | 0.33% |
6 | or other cns depressants | | | | | | | 2 | 0.33% |
7 | in an increase in | | | | | | | 2 | 0.33% |
8 | result in an increase | | | | | | | 2 | 0.33% |
9 | click here for prescribing | | | | | | | 2 | 0.33% |
10 | please click here for | | | | | | | 2 | 0.33% |
11 | prescribing information las vegas | | | | | | | 2 | 0.33% |
12 | information las vegas nv | | | | | | | 2 | 0.33% |
13 | las vegas nv forte | | | | | | | 2 | 0.33% |
14 | evaluation and mitigation strategy | | | | | | | 2 | 0.33% |
15 | pharmacy partnering company partnering | | | | | | | 2 | 0.33% |
16 | with benzodiazepines or other | | | | | | | 2 | 0.33% |
17 | use of prolate or | | | | | | | 2 | 0.33% |
18 | cytochrome p450 3a4 interaction | | | | | | | 2 | 0.33% |
19 | or nalocet tablets and | | | | | | | 2 | 0.33% |
20 | neonatal opioid withdrawal syndrome | | | | | | | 2 | 0.33% |
21 | vegas nv forte biopharma | | | | | | | 2 | 0.33% |
22 | ensure that appropriate treatment | | | | | | | 1 | 0.16% |
23 | that appropriate treatment will | | | | | | | 1 | 0.16% |
24 | and ensure that appropriate | | | | | | | 1 | 0.16% |
25 | appropriate treatment will be | | | | | | | 1 | 0.16% |
26 | available cytochrome p450 3a4 | | | | | | | 1 | 0.16% |
27 | p450 3a4 interaction the | | | | | | | 1 | 0.16% |
28 | the patient of the | | | | | | | 1 | 0.16% |
29 | syndrome and ensure that | | | | | | | 1 | 0.16% |
30 | withdrawal syndrome and ensure | | | | | | | 1 | 0.16% |
31 | risk of neonatal opioid | | | | | | | 1 | 0.16% |
32 | the risk of neonatal | | | | | | | 1 | 0.16% |
33 | of the risk of | | | | | | | 1 | 0.16% |
34 | patient of the risk | | | | | | | 1 | 0.16% |
35 | interaction the concomitant use | | | | | | | 1 | 0.16% |
36 | advise the patient of | | | | | | | 1 | 0.16% |
37 | woman advise the patient | | | | | | | 1 | 0.16% |
38 | pregnant woman advise the | | | | | | | 1 | 0.16% |
39 | a pregnant woman advise | | | | | | | 1 | 0.16% |
40 | in a pregnant woman | | | | | | | 1 | 0.16% |